Aarvik
Aarvik Therapeutics Showcases Novel ADC Molecules Based On MUTTA™ and AQUALINK™ Platforms at AACR 2026
Aarvik Therapeutics Announces Investment by Laurus Labs in Aarvik Series Seed 2 Round
Aarvik Therapeutics Announces Successful Series Seed 2 Financing Round
Aarvik Therapeutics Announces Option Exercise by Collaboration Partner ArriVent BioPharma
Aarvik Therapeutics Announces Validation of Novel Tetravalent Antibody Platform
Aarvik Therapeutics and ArriVent Biopharma Announce Research Collaboration to Advance Novel Oncology Drug Candidate Using Aarvik’s Proprietary Modular Antibody Platform
Aarvik Therapeutics Appoints Dr. Richard Scheller to Board of Directors, Dr. Melissa Starovasnik to Scientific Advisory Board, and Announces Scientific Team
Aarvik Therapeutics (formerly Aarkus Therapeutics) Announces Successful Series Seed Financing
Aarvik Therapeutics Launches with a Novel Modular Antibody Technology Platform
By James Waldron FierceBiotech
You cannot copy content of this page
Javascript not detected. Javascript required for this site to function. Please enable it in your browser settings and refresh this page.
